The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


H2/22 Slated to Be Catalyst Rich for Pharma Co.

Research Report
  ()
Streetwise looks over the latest events surrounding Syros Pharmaceuticals after a Roth Capital Partners report shared that their newest updates could bolster the cash position of the firm and, thus, allow it to continue advancing all of its clinical programs.

New Improved Drug Expected to Get FDA Approval Next Month

Research Report
  ()
Greenlighting of its medication for urea cycle disorders is the first of a trio of catalysts anticipated for this U.S. pharma firm in 2022, noted a ROTH Capital Partners report. Streetwise reviews the newest updates in this drug development and the company's stock.

Firm Reports Encouraging Trial Results in Cystinosis

Research Report
  ()
New data from a Wedbush report shows that study patients experienced improvements in visual-motor integration, motor coordination, and visual perception. Streetwise Reports takes a deeper look at Avrobio Inc.

Coverage Launched on Co. in Alzheimer's Drug Space

Research Report
  ()
This biopharma's therapeutic candidates for central nervous system diseases stand out because of their selective and specific mechanism of action, noted a Leede Jones Gable report.

Clinical Catalysts for Biotech's Stock On Track for Mid 2022

Research Report
  ()
Upcoming potential stock-moving events include new data concerning the company's lead therapeutic candidate for age-related eye diseases, noted a ROTH Capital Partners report.

Biopharma Co. to Launch Two Clinical Trials This Year

Research Report
  ()
Success in either program, atopic dermatitis or asthma, "could lead to multiblockbuster sales," noted a ROTH Capital Partners report.

First Results From Biotech Co.'s Lymphoma Program Are Impressive

Research Report
  ()
This data will be presented at the 2022 annual meeting of the European Hematology Association on June 11th, noted a ROTH Capital Partners report.

Analyst Says Avivagen Is a Strong Buy

Contributed Opinion
  ()
With Avivagen's breakthrough product relishing in its success, Analyst Clive Maund reviews if he believes it is now a formidable contender as a Buy.

Pilot Launch of VLN Cigarettes in Progress

Research Report
  ()
These "very low nicotine" tobacco products will be an alternative for smokers when the FDA effects its imminent menthol cigarette ban, noted a ROTH Capital Partners report.

Biotech Co. Advances COVID-19 Vaccines Toward Approval

Research Report
  ()
They include booster vaccines for different age groups of children and an Omicron-targeting booster for adults, noted an H.C. Wainwright & Co. report.

Could a New Prescription Drug Treat This Common Ailment?

Research Report
  ()
The combination drug Halo-Lido is poised to be the first-of-its-kind prescription treatment approved by the U.S. Food and Drug Administration for this prevalent medical condition, noted a DawsonJames report.

Senior Biotech Analyst's Top 3 Stocks

  ()
Streetwise Reports recently spoke to renowned biotech expert John Vandermosten (CFA) about three of his favorite healthcare companies that are addressing as-of-yet unmet market needs.

Life Sciences Co. Expected to Attract Partners, Big Pharma

Research Report
  ()
"We foresee continued execution on its developmental strategy," noted Argus Research on this development stage biotech company tackling neurodegenerative diseases.

Showing Results: 1 to 25 of 109 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We have a Buy recommendation on OMM."
– Chris Temple, The National Investor
"We have a Buy recommendation on QPM."
– Chris Temple, The National Investor
"MMG is starting to look like a Buy here."
– Clive Maund, CliveMaund.com
"POE is planning to liquidate the Thai assets and pay out shareholders."
– Chen Lin, What Is Chen Buying? What Is Chen Selling?